Effects of hormone replacement therapy on clinical fractures and height loss: The heart and estrogen/progestin replacement study (HERS)

American Journal of Medicine

Volumn 110, Issue 6, 2001, Pages 442-450

  Cauley, Jane A ^a   Black, Dennis M ^b   Barrett Connor, Elizabeth ^c   Harris, Fran ^b   Shields, Kathleen ^d   Applegate, William ^e   Cummings, Steven R ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WYETH AYERST RESEARCH   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CONJUGATED ESTROGEN; DIURETIC AGENT; MEDROXYPROGESTERONE ACETATE; NITRATE; STATIN;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; FEMALE; FOLLOW UP; HEALTH STATUS; HIP FRACTURE; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; SPINE FRACTURE; WRIST FRACTURE;

AGED; BODY HEIGHT; BONE DENSITY; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; LIFE STYLE; MEDROXYPROGESTERONE; POSTMENOPAUSE; PROGESTERONE CONGENERS;

EID: 0035870693     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00647-7     Document Type: Article

References (31)

1. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 122:1995;9-16.
2. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
3. Naessen T., Persson I., Adami H.O., Bergstrom R., Bergkvist L. Hormone replacement therapy and the risk for the first hip fracture. A prospective, population-based cohort study. Ann Intern Med. 113:1990;95-103.
4. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int. 1994;5:23-29.
5. Weiss N.S., Ure C.L., Ballard J.H., Williams A.R., Daling J.R. Decreased risk of fractures of hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 303:1980;1195-1198.
6. Anonymous. Osteoporosis. Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 8:1998;1-85.
7. Cauley J.A., Cummings S.R., Black D.M., Mascioli S.R., Seeley D.G. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 163:1990;1438-1444.
8. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., Beckman E.M. Estrogen replacement therapy I a 10-year prospective study in the relationship to osteoporosis . Obstet Gynecol. 53:1979;277-281.
9. Lindsay R., Hart D.M., Forrest C., Baird C. Prevention of spinal osteoporosis in oophorectomized women. Lancet. ii:1980;1151-1153.
10. Lufkin E.G., Wahner H.W., O'Fallon W.M., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 117:1992;1-9.
11. Windeler J., Lange S. Events per person year - a dubious concept. BMJ. 310:1995;454-456.
12. Wimalawansa S.J. A four-year randomized controlled trial of hormone replacement and biphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 104:1998;219-226.
13. Bone H.G., Greenspan S.L., McKeever C., et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 85:2000;720-726.
14. Komulainen M.H., Kroger H., Tuppurainen M.T., et al. Hormone replacement therapy and vitamin D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas. 31:1998;45-54.
15. Mosekilde L., Beck-Nielsen H., Sorensen O.H., et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention study. Maturitas. 36:2000;181-193.
16. Grady D., Applegate W., Bush T., Furberg C., Riggs B., Hulley S.B. Heart and Estrogen/progestin Replacement Study (HERS) design, methods and baseline characteristics. Control Clin Trials. 19:1998;314-335.
17. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
18. Kanis J.A., Melton L.J. III, Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 9:1994;1137-1141.
19. Black D.M., Palermo L., Nevitt M.C., Genant H.K., Christensen L., Cummings S.R. Defining incident vertebral deformity a prospective comparison of several approaches . J Bone Miner Res. 14:1999;90-101.
20. Paganini-Hill A., Ross R.K., Gerkins V.R., Henderson B.E., Arthur M., Mack T.M. Menopausal estrogen therapy and hip fractures. Ann Intern Med. 95:1981;28-31.
21. Kreiger N., Kelsey J.L., Holford T.R., O'Conner T. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol. 116:1982;141-148.
22. Hutchinson T.A., Polansky S.M., Feinstein A.R. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet. 2:1979;705-709.
23. Black D.M., Cummings S.R., Karpf D.B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
24. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 280:1998;2077-2082.
25. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 282:1999;1344-1352.
26. Ettinger B., Mitlak B.H., Nickelson T., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from 3-year randomized clinical trial . JAMA. 282:1999;637-645.
27. Cooper C., Melton L.J. Vertebral fractures how large is the silent epidemic . Br Med J. 304:1992;793-794.
28. Huang C., Ross P.P., Lydick E., Davis J.W., Wasnich R.D. Contributions of vertebral fractures to stature loss among elderly Japanese-American women in Hawaii. J Bone Miner Res. 11:1996;408-411.
29. Effects of hormone therapy on bone mineral density. JAMA. 276:1996;1389-1396.
30. Wasnich R.D., Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone. J Clin Endocrinol Metab. 85:2000;231-236.
31. Riggs B.L., Melton L.J., O'Fallon W.M. Drug therapy for vertebral fractures in osteoporosis evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy . Bone. 18:1996;197S-201S.